Developer docs
API playgroundTry for free, no card

Search company profiles

CDx Diagnostics

Full company profile

uuid0000w41

Namestring
CDx Diagnostics
Legal namestring
CDx Diagnostics, Inc.
Company typeenum
Private
Founded yearint
2010
Descriptiontext

CDx Diagnostics, Inc. is a Delaware-incorporated specialty diagnostics company headquartered in Suffern, New York, with 101-250 employees. Founded prior to 2012, the company has developed and commercialized WATS3D (Wide-Area Transepithelial Sampling with 3D Analysis), an AI-powered diagnostic platform designed to detect pre-cancerous cells in the esophagus and oral cavity. The platform combines a specially designed abrasive brush that collects wide-area, full-thickness transepithelial tissue specimens, 3D computer-assisted tissue analysis synthesizing over 100 one-micron optical slices into a single 3D image, and a proprietary neural network (originally developed from U.S. Strategic Defense Initiative missile defense technology) that selects suspicious areas for pathologist review. Analysis is performed in CDx's CLIA-certified, CAP-accredited, New York state-licensed clinical laboratory.

The company's business model is a per-test laboratory fee reimbursed by commercial payors, Medicare/Medicare Advantage, and federal healthcare channels. WATS3D is covered as an in-network procedure under contracts reaching 73 million lives (~20% of US population) including BCBS of Massachusetts, BCBS of South Carolina, BCBS Kansas City, Highmark, HMSA, and Avalon Healthcare Solutions, plus a GSA Federal Supply Schedule contract serving 12.5 million veterans and active-duty members. Go-to-market combines a sales-led field force targeting GI practices and academic medical centers with channel partnerships via payors and government, supported by direct-to-patient demand generation through a Physician Finder tool and Patient Financial Assistance Program.

The company has processed over 400,000 WATS3D procedures across 10+ years of clinical use, with FDA Breakthrough Device Designation granted in July 2025 and five major GI society endorsements (ASGE, SAGES TAVAC, AFS, AGA). The product portfolio includes WATS3D (core), OralCDx (oral cancer brush biopsy), and EndoCDx (pipeline endoscopic diagnostic), with an R&D pipeline targeting cancers of the throat, bile duct, liver, pancreas, stomach, and IBD-affected colon. CDx is backed by Galen Partners (growth equity).

Short descriptiontext

CDx Diagnostics is a specialty AI-powered diagnostics company that developed WATS3D, an AI-driven platform for detecting pre-cancerous cells in the esophagus and oral cavity, serving gastroenterologists, endoscopists, GI pathologists, and commercial/federal payors across the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSuffern, United States
HQ citystring
Suffern
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI digital pathology, esophageal cancer diagnostics, Barrett's esophagus screening, brush biopsy testing, specialty clinical laboratory
Industry3 codes
PRIMARYHLAAAMAB
Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAFAMAA
Anatomic Pathology (Histopathology & Cytopathology)
NAICS code3 codes
  • Medical and Diagnostic Laboratories62151
  • Medical and Diagnostic Laboratories6215
  • Medical Laboratories621511
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Specialty cancer diagnostics (esophageal and oral precancer detection)
GTM motion6 records

Each record includes

Type, Description, Source

Revenue model3 records
1WATS3D Per-Test Lab Diagnostic Fee
TypeUsage Based
Description

Per-procedure reimbursement from commercial payors, Medicare and Medicare Advantage plans, and patients. WATS3D is billed as a covered benefit under 73 million covered lives across contracted insurers including BCBS of Massachusetts, BCBS of South Carolina, BCBS Kansas City, HMSA, Highmark plans and Avalon. Self-pay/financial assistance available for uninsured patients.

cdxdiagnostics.com
2Federal Government Lab Services (GSA)
TypeManaged Services
Description

Per-test revenue under Veterans Affairs Federal Supply Schedule (VA FSS) Contract #36F79721D0050, providing WATS3D to VA hospitals, Department of Defense, Indian Health Services and federal prisons, reaching 12.5 million veteran and active-duty members at the best commercial rate.

cdxdiagnostics.com
3EndoCDx and R&D Pipeline Future Tests
TypeUsage Based
Description

Future pipeline of CDx platform applications to prevent cancers of the throat, bile duct, liver, pancreas, stomach, and surveillance for dysplasia of the colon in patients with IBD — extending the per-test lab fee model to new indications.

cdxdiagnostics.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1Per-procedure lab test reimbursement, covered under contracts covering 73 million lives
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed; reimbursed by insurance payors, Medicare, Medicare Advantage, VA FSS and self-pay. Patient Financial Assistance Program with flexible payment plans available; application processing ~2 weeks.

cdxdiagnostics.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1WATS3D
Description

Wide Area Transepithelial Sampling with 3D Analysis - AI-powered diagnostic platform for detection and surveillance of Barrett's esophagus and esophageal dysplasia.

cdxdiagnostics.com
+2 more records
Core offering1 text field

CDx Diagnostics operates a CLIA-certified specialty clinical laboratory that performs the proprietary WATS3D (Wide-Area Transepithelial Sampling with 3D Analysis) test, an AI-powered diagnostic service that uses a specially designed brush to collect wide-area, full-thickness esophageal tissue specimens and applies a neural-network 3D computer-assisted analysis to detect Barrett's esophagus and precancerous cells missed by standard forceps biopsy. The portfolio also includes the OralCDx brush biopsy test for oral precancer detection and the EndoCDx endoscopic diagnostic, with services delivered to gastroenterology practices, hospitals, payors and federal healthcare facilities on a per-procedure reimbursed basis.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

CDx Diagnostics is a specialty diagnostics company offering a platform-plus-modules architecture centered on its proprietary AI-powered tissue analysis and 3D imaging platform. The flagship product is WATS3D (Wide-Area Transepithelial Sampling with 3D Analysis), an AI-powered diagnostic system for esophageal cancer prevention that uses a specially designed brush to collect wide-area, full-thickness transepithelial tissue specimens which are then processed through 3D computer-assisted analysis and AI neural network identification of suspicious cells, with final review by trained GI pathologists in the company's CLIA-certified laboratory. OralCDx is a complementary brush biopsy test for oral cancer detection, and EndoCDx is referenced in the navigation as a related endoscopic diagnostic offering. The platform is supported by in-house laboratory services, pathology partnership programs, physician finder tools, patient financial assistance programs, and educational resources (Patient Pocket Guide, Brochure). Recent pipeline initiatives include applying the next-generation CDx diagnostic platform to prevent cancers of the throat, bile duct, liver, pancreas, stomach, and IBD-affected colon.

Product and service6 records
1WATS3D
CategoryCore diagnostic product
Description

WATS3D (Wide-Area Transepithelial Sampling with 3D Analysis) is an AI-powered diagnostic test that uses a specially designed brush to collect a wide-area, full-thickness transepithelial tissue sample from the esophagus during upper endoscopy. The specimen is processed in CDx's CLIA-certified laboratory through 3D computer-assisted analysis with an AI neural network that highlights suspicious cells for review by trained GI pathologists, significantly increasing detection of Barrett's esophagus and esophageal dysplasia compared with standard forceps biopsy.

2OralCDx
CategorySub-product / diagnostic test
Description

OralCDx is a brush biopsy test for oral cancer detection and prevention, designed to identify precancerous changes in the oral cavity. The test uses a specially designed brush (LongBrush) to collect tissue samples that are analyzed for early detection of oral precancerous lesions.

3EndoCDx
CategorySub-product / diagnostic test
Description

EndoCDx is a related endoscopic diagnostic offering in CDx Diagnostics' portfolio, referenced in the site's navigation alongside WATS3D and OralCDx as an endoscopic-based diagnostic product for the company's R&D and product pipeline.

4CDx Diagnostics Laboratory Services
CategoryService / supporting offering
Description

Diagnostic assessments and laboratory analysis services performed at CDx Diagnostics' CLIA-certified, CAP-accredited, New York state-licensed clinical laboratory in Suffern, NY. Includes tissue specimen processing, 3D imaging, AI-powered analysis and pathologist review for WATS3D and related tests.

5WATS3D Patient Pocket Guide & Patient Brochure
CategoryPatient resources / educational materials
Description

Patient-facing educational materials including a WATS3D Patient Pocket Guide and WATS3D Patient Brochure that help patients and doctors discuss the benefits of WATS3D during upper endoscopy for managing Barrett's esophagus and chronic heartburn.

6Patient Financial Assistance Program
CategoryPatient services / billing
Description

Financial assistance program that may reduce patient responsibility based on financial need, available with online application forms in English and Spanish and support from Billing Care Specialists at (800)-352-8619.

Scale indicator25 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1American Gastroenterological Association (AGA) and Society of American Gastrointestinal and Endoscopic Surgeons (SAGES)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-05-02
Description

Collaborative study with Dr. Michael Smith, Dr. Vivek Kaul, Mendel Singer Ph.D., and Dr. Robert Odze selected for podium presentation at DDW 2025 (May 2, 2025), advancing understanding of WATS3D-detected lesion progression risk. WATS3D included in AGA Clinical Practice Update (2022) and SAGES TAVAC analysis (2020).

cdxdiagnostics.com
2Dr. Sidney Olefson (Prima CARE, Massachusetts/Rhode Island)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-03-25
Description

Dr. Sidney Olefson of Prima CARE developed an alternative WATS3D specimen acquisition technique (announced March 25, 2025) that enhances cellular adequacy for AI and pathologist analysis. CDx highlighted this innovation as an important evolution of the WATS3D test platform.

cdxdiagnostics.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-06-14
Description

CDx signed an agreement with laboratory benefits management provider Avalon Healthcare Solutions (Tampa, FL) on June 14, 2022, making CDx an in-network specialty anatomic pathology laboratory for Avalon's client BlueCross BlueShield of South Carolina and 565,000 commercial and Medicare Advantage members.

Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-11-17
Description

Highmark BCBS plans in Delaware, Pennsylvania, and West Virginia designated WATS3D as medically necessary on November 17, 2021, covering more than 3.6 million Highmark members. CDx subsequently joined the Commercial and Medicare networks effective May 2022. Brought total CDx-contracted health plan membership to 36 million at that time.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-03-09
Description

BCBS of Kansas City granted WATS3D a positive medically necessary designation effective March 9, 2021, covering 611,000 members across Kansas and Missouri. Fifth organization to add WATS3D to its benefits in the prior quarter.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-01-26
Description

WATS3D deemed medically necessary by BCBS of South Carolina (January 26, 2021), covering over 1.2 million members. Subsequently joined Avalon Healthcare Solutions in-network lab network in June 2022 covering 565,000 commercial and Medicare Advantage members.

Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-12-15
Description

CDx awarded GSA Contract #36F79721D0050 on December 15, 2020, providing WATS3D through the Veterans Affairs Federal Supply Schedule (VA FSS) to VA hospitals, Department of Defense, Indian Health Services and federal prisons. Gives 12.5 million veteran and active-duty members access to WATS3D at the best commercial rate.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-08-11
Description

CDx contracted with HMSA (largest insurer in Hawaii, BCBS licensee) effective August 11, 2020, making WATS3D available to all 800,000 members and designated medically necessary per ASGE guidelines.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-01-21
Description

CDx Diagnostics contracted as in-network provider with BCBS of Massachusetts effective January 21, 2020, covering nearly 3 million members statewide. WATS3D designated as medically necessary for the screening and surveillance of Barrett's esophagus under this contract.

10American Society for Gastrointestinal Endoscopy (ASGE)
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

WATS3D included in the ASGE Standards of Practice Committee's guideline for the screening and surveillance of Barrett's esophagus (September 4, 2019). Provides ongoing clinical practice validation and inclusion as standard of care in published ASGE Guidelines.

cdxdiagnostics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cellvizio optical biopsy platform enables in-vivo real-time cellular imaging during endoscopy, competing directly with WATS3D in Barrett's esophagus and esophageal cancer screening. Both target the same GI workflow and reimbursement pathway as adjuncts or alternatives to forceps biopsy.

TypeDirect peer
Description

NvisionVLE optical coherence tomography (OCT) imaging system used during upper endoscopy for Barrett's esophagus surveillance. Competes with WATS3D by offering real-time volumetric tissue imaging that could reduce reliance on physical tissue sampling and external lab analysis.

TypeEmerging player
Description

AI-powered digital pathology company (FDA-authorized prostate cancer detection; expanding into other tissue types). While currently focused on prostate and other solid tumors rather than BE, Paige's AI pathology approach is architecturally comparable to WATS3D and could expand into GI applications.

TypeEmerging player
Description

AI-powered cancer diagnostics platform deployed in pathology labs worldwide, with FDA-cleared products for breast and prostate cancer detection. Shares the AI-on-histopathology model with WATS3D and represents a potential entrant into the Barrett's esophagus and GI surveillance market.

TypeEmerging player
Description

AI pathology company partnering with pharmaceutical and diagnostic companies to develop computational pathology products. Operates in the same AI digital pathology space as WATS3D with adjacent oncology applications and could enter GI pathology over time.

TypeBroad incumbent
Description

Specialty oncology laboratory offering comprehensive molecular and anatomic pathology services, including GI cancer testing. As a broad specialty lab with established payor contracts and a CLIA-certified infrastructure, NeoGenomics could expand into AI-augmented BE/dysplasia testing competing with WATS3D.

7Cernostics (acquired by Alpine Immune Sciences)
TypeDirect peer
Description

Was a direct competitor in tissue-based diagnostics for Barrett's esophagus risk stratification (TissueCypher), providing a similar lab-based AI-on-tissue approach to predicting progression to esophageal cancer. Acquired by Alpine Immune Sciences in 2022, but the technology represents a directly comparable prior peer.

TypeBroad incumbent
Description

Cancer screening and diagnostics company (Cologuard for CRC screening) with established commercial lab, payor contracts, and direct-to-consumer marketing infrastructure. Could expand from CRC into esophageal cancer screening, overlapping with WATS3D's screening-of-pre-cancer positioning.

TypeBroad incumbent
Description

Owns the Barrx radiofrequency ablation system for treating Barrett's esophagus. As the dominant player in BE management downstream of diagnosis, Medtronic is a natural strategic partner - or competitor if it bundles WATS3D-alternative diagnostics with its ablation franchise.

TypeBroad incumbent
Description

Endoscope manufacturer developing AI-enhanced endoscopy (i-scan, Optical Enhancement) and exploring AI-powered lesion detection in GI. Provides an OEM/embedded route through which competing AI diagnostic capabilities could be bundled with the endoscopy hardware itself, threatening standalone platforms like WATS3D.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers17 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CDx Diagnostics

Specialty cancer diagnostics (esophageal and oral precancer detection)cdxdiagnostics.com

CDx Diagnostics is a specialty AI-powered diagnostics company that developed WATS3D, an AI-driven platform for detecting pre-cancerous cells in the esophagus and oral cavity, serving gastroenterologists, endoscopists, GI pathologists, and commercial/federal payors across the United States.

What CDx Diagnostics does

CDx Diagnostics, Inc. is a Delaware-incorporated specialty diagnostics company headquartered in Suffern, New York, with 101-250 employees. Founded prior to 2012, the company has developed and commercialized WATS3D (Wide-Area Transepithelial Sampling with 3D Analysis), an AI-powered diagnostic platform designed to detect pre-cancerous cells in the esophagus and oral cavity. The platform combines a specially designed abrasive brush that collects wide-area, full-thickness transepithelial tissue specimens, 3D computer-assisted tissue analysis synthesizing over 100 one-micron optical slices into a single 3D image, and a proprietary neural network (originally developed from U.S. Strategic Defense Initiative missile defense technology) that selects suspicious areas for pathologist review. Analysis is performed in CDx's CLIA-certified, CAP-accredited, New York state-licensed clinical laboratory.

The company's business model is a per-test laboratory fee reimbursed by commercial payors, Medicare/Medicare Advantage, and federal healthcare channels. WATS3D is covered as an in-network procedure under contracts reaching 73 million lives (~20% of US population) including BCBS of Massachusetts, BCBS of South Carolina, BCBS Kansas City, Highmark, HMSA, and Avalon Healthcare Solutions, plus a GSA Federal Supply Schedule contract serving 12.5 million veterans and active-duty members. Go-to-market combines a sales-led field force targeting GI practices and academic medical centers with channel partnerships via payors and government, supported by direct-to-patient demand generation through a Physician Finder tool and Patient Financial Assistance Program.

The company has processed over 400,000 WATS3D procedures across 10+ years of clinical use, with FDA Breakthrough Device Designation granted in July 2025 and five major GI society endorsements (ASGE, SAGES TAVAC, AFS, AGA). The product portfolio includes WATS3D (core), OralCDx (oral cancer brush biopsy), and EndoCDx (pipeline endoscopic diagnostic), with an R&D pipeline targeting cancers of the throat, bile duct, liver, pancreas, stomach, and IBD-affected colon. CDx is backed by Galen Partners (growth equity).

CDx Diagnostics firmographics

Firmographics
Name
CDx Diagnostics
Legal name
CDx Diagnostics, Inc.
Website
https://cdxdiagnostics.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Short description
CDx Diagnostics is a specialty AI-powered diagnostics company that developed WATS3D, an AI-driven platform for detecting pre-cancerous cells in the esophagus and oral cavity, serving gastroenterologists, endoscopists, GI pathologists, and commercial/federal payors across the United States.
Ownership category
akta.pro rank

CDx Diagnostics industry classification

Industry
Product category
Specialty cancer diagnostics (esophageal and oral precancer detection)
NAICS
Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAMAB
Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAFAMAA
Anatomic Pathology (Histopathology & Cytopathology)

Keywords

  • AI digital pathology
  • Esophageal cancer diagnostics
  • Barrett's esophagus screening
  • Brush biopsy testing
  • Specialty clinical laboratory

Where CDx Diagnostics is headquartered

Location

Headquarters

HQ city
Suffern
HQ country
United States
HQ region
North America

Offices2 records

Markets served

CDx Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. WATS3D Per-Test Lab Diagnostic Fee: Per-procedure reimbursement from commercial payors, Medicare and Medicare Advantage plans, and patients. WATS3D is billed as a covered benefit under 73 million covered lives across contracted insurers including BCBS of Massachusetts, BCBS of South Carolina, BCBS Kansas City, HMSA, Highmark plans and Avalon. Self-pay/financial assistance available for uninsured patients.
  2. Federal Government Lab Services (GSA): Per-test revenue under Veterans Affairs Federal Supply Schedule (VA FSS) Contract #36F79721D0050, providing WATS3D to VA hospitals, Department of Defense, Indian Health Services and federal prisons, reaching 12.5 million veteran and active-duty members at the best commercial rate.
  3. EndoCDx and R&D Pipeline Future Tests: Future pipeline of CDx platform applications to prevent cancers of the throat, bile duct, liver, pancreas, stomach, and surveillance for dysplasia of the colon in patients with IBD — extending the per-test lab fee model to new indications.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPer-procedure lab test reimbursement, covered under contracts covering 73 million lives

Go-to-market motion6 records

Distribution channels5 records

Marketing channels9 records

CDx Diagnostics product offering

Product offering

Core offering

CDx Diagnostics operates a CLIA-certified specialty clinical laboratory that performs the proprietary WATS3D (Wide-Area Transepithelial Sampling with 3D Analysis) test, an AI-powered diagnostic service that uses a specially designed brush to collect wide-area, full-thickness esophageal tissue specimens and applies a neural-network 3D computer-assisted analysis to detect Barrett's esophagus and precancerous cells missed by standard forceps biopsy. The portfolio also includes the OralCDx brush biopsy test for oral precancer detection and the EndoCDx endoscopic diagnostic, with services delivered to gastroenterology practices, hospitals, payors and federal healthcare facilities on a per-procedure reimbursed basis.

Product overview

CDx Diagnostics is a specialty diagnostics company offering a platform-plus-modules architecture centered on its proprietary AI-powered tissue analysis and 3D imaging platform. The flagship product is WATS3D (Wide-Area Transepithelial Sampling with 3D Analysis), an AI-powered diagnostic system for esophageal cancer prevention that uses a specially designed brush to collect wide-area, full-thickness transepithelial tissue specimens which are then processed through 3D computer-assisted analysis and AI neural network identification of suspicious cells, with final review by trained GI pathologists in the company's CLIA-certified laboratory. OralCDx is a complementary brush biopsy test for oral cancer detection, and EndoCDx is referenced in the navigation as a related endoscopic diagnostic offering. The platform is supported by in-house laboratory services, pathology partnership programs, physician finder tools, patient financial assistance programs, and educational resources (Patient Pocket Guide, Brochure). Recent pipeline initiatives include applying the next-generation CDx diagnostic platform to prevent cancers of the throat, bile duct, liver, pancreas, stomach, and IBD-affected colon.

Differentiator

Problem solved

Functional benefit

Brands

  • WATS3D: Wide Area Transepithelial Sampling with 3D Analysis - AI-powered diagnostic platform for detection and surveillance of Barrett's esophagus and esophageal dysplasia.
  • OralCDx
  • EndoCDx

Products and services

  • WATS3D WATS3D (Wide-Area Transepithelial Sampling with 3D Analysis) is an AI-powered diagnostic test that uses a specially designed brush to collect a wide-area, full-thickness transepithelial tissue sample from the esophagus during upper endoscopy. The specimen is processed in CDx's CLIA-certified laboratory through 3D computer-assisted analysis with an AI neural network that highlights suspicious cells for review by trained GI pathologists, significantly increasing detection of Barrett's esophagus and esophageal dysplasia compared with standard forceps biopsy.
  • OralCDx OralCDx is a brush biopsy test for oral cancer detection and prevention, designed to identify precancerous changes in the oral cavity. The test uses a specially designed brush (LongBrush) to collect tissue samples that are analyzed for early detection of oral precancerous lesions.
  • EndoCDx EndoCDx is a related endoscopic diagnostic offering in CDx Diagnostics' portfolio, referenced in the site's navigation alongside WATS3D and OralCDx as an endoscopic-based diagnostic product for the company's R&D and product pipeline.
  • CDx Diagnostics Laboratory Services Diagnostic assessments and laboratory analysis services performed at CDx Diagnostics' CLIA-certified, CAP-accredited, New York state-licensed clinical laboratory in Suffern, NY. Includes tissue specimen processing, 3D imaging, AI-powered analysis and pathologist review for WATS3D and related tests.
  • WATS3D Patient Pocket Guide & Patient Brochure Patient-facing educational materials including a WATS3D Patient Pocket Guide and WATS3D Patient Brochure that help patients and doctors discuss the benefits of WATS3D during upper endoscopy for managing Barrett's esophagus and chronic heartburn.
  • Patient Financial Assistance Program Financial assistance program that may reduce patient responsibility based on financial need, available with online application forms in English and Spanish and support from Billing Care Specialists at (800)-352-8619.

Companies that use CDx Diagnostics

Customer profile

Named customers17 records

Segments5 records

Ideal customer profiles3 records

CDx Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

CDx Diagnostics partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered flagship, minor and core.

  • American Gastroenterological Association (AGA) and Society of American Gastrointestinal and Endoscopic Surgeons (SAGES)flagshipStrategic or Co-development Partner · 2 May 2025Collaborative study with Dr. Michael Smith, Dr. Vivek Kaul, Mendel Singer Ph.D., and Dr. Robert Odze selected for podium presentation at DDW 2025 (May 2, 2025), advancing understanding of WATS3D-detected lesion progression risk. WATS3D included in AGA Clinical Practice Update (2022) and SAGES TAVAC analysis (2020).
  • Dr. Sidney Olefson (Prima CARE, Massachusetts/Rhode Island)minorStrategic or Co-development Partner · 25 March 2025Dr. Sidney Olefson of Prima CARE developed an alternative WATS3D specimen acquisition technique (announced March 25, 2025) that enhances cellular adequacy for AI and pathologist analysis. CDx highlighted this innovation as an important evolution of the WATS3D test platform.
  • Avalon Healthcare SolutionscoreChannel Partner/ Reseller/ Distributor · 14 June 2022CDx signed an agreement with laboratory benefits management provider Avalon Healthcare Solutions (Tampa, FL) on June 14, 2022, making CDx an in-network specialty anatomic pathology laboratory for Avalon's client BlueCross BlueShield of South Carolina and 565,000 commercial and Medicare Advantage members.
  • Highmark Blue Cross Blue Shield (Delaware, Pennsylvania, West Virginia)flagshipChannel Partner/ Reseller/ Distributor · 17 November 2021Highmark BCBS plans in Delaware, Pennsylvania, and West Virginia designated WATS3D as medically necessary on November 17, 2021, covering more than 3.6 million Highmark members. CDx subsequently joined the Commercial and Medicare networks effective May 2022. Brought total CDx-contracted health plan membership to 36 million at that time.
  • Blue Cross Blue Shield of Kansas CitycoreChannel Partner/ Reseller/ Distributor · 9 March 2021BCBS of Kansas City granted WATS3D a positive medically necessary designation effective March 9, 2021, covering 611,000 members across Kansas and Missouri. Fifth organization to add WATS3D to its benefits in the prior quarter.
  • BlueCross BlueShield of South CarolinacoreChannel Partner/ Reseller/ Distributor · 26 January 2021WATS3D deemed medically necessary by BCBS of South Carolina (January 26, 2021), covering over 1.2 million members. Subsequently joined Avalon Healthcare Solutions in-network lab network in June 2022 covering 565,000 commercial and Medicare Advantage members.
  • U.S. Federal Government (Veterans Administration, Department of Defense, Indian Health Services, Federal Prisons)flagshipChannel Partner/ Reseller/ Distributor · 15 December 2020CDx awarded GSA Contract #36F79721D0050 on December 15, 2020, providing WATS3D through the Veterans Affairs Federal Supply Schedule (VA FSS) to VA hospitals, Department of Defense, Indian Health Services and federal prisons. Gives 12.5 million veteran and active-duty members access to WATS3D at the best commercial rate.
  • Hawaii Medical Service Association (HMSA)coreChannel Partner/ Reseller/ Distributor · 11 August 2020CDx contracted with HMSA (largest insurer in Hawaii, BCBS licensee) effective August 11, 2020, making WATS3D available to all 800,000 members and designated medically necessary per ASGE guidelines.
  • Blue Cross Blue Shield of MassachusettscoreChannel Partner/ Reseller/ Distributor · 21 January 2020CDx Diagnostics contracted as in-network provider with BCBS of Massachusetts effective January 21, 2020, covering nearly 3 million members statewide. WATS3D designated as medically necessary for the screening and surveillance of Barrett's esophagus under this contract.
  • American Society for Gastrointestinal Endoscopy (ASGE)flagshipStrategic or Co-development PartnerWATS3D included in the ASGE Standards of Practice Committee's guideline for the screening and surveillance of Barrett's esophagus (September 4, 2019). Provides ongoing clinical practice validation and inclusion as standard of care in published ASGE Guidelines.

Scale indicators25 records

Recent moves6 records

Expansion highlights6 records

CDx Diagnostics competitors and assessment

Company assessment

Direct peers

  • Mauna Kea Technologies: Cellvizio optical biopsy platform enables in-vivo real-time cellular imaging during endoscopy, competing directly with WATS3D in Barrett's esophagus and esophageal cancer screening. Both target the same GI workflow and reimbursement pathway as adjuncts or alternatives to forceps biopsy.
  • NinePoint Medical: NvisionVLE optical coherence tomography (OCT) imaging system used during upper endoscopy for Barrett's esophagus surveillance. Competes with WATS3D by offering real-time volumetric tissue imaging that could reduce reliance on physical tissue sampling and external lab analysis.
  • Cernostics (acquired by Alpine Immune Sciences): Was a direct competitor in tissue-based diagnostics for Barrett's esophagus risk stratification (TissueCypher), providing a similar lab-based AI-on-tissue approach to predicting progression to esophageal cancer. Acquired by Alpine Immune Sciences in 2022, but the technology represents a directly comparable prior peer.

Emerging players

  • Paige.AI: AI-powered digital pathology company (FDA-authorized prostate cancer detection; expanding into other tissue types). While currently focused on prostate and other solid tumors rather than BE, Paige's AI pathology approach is architecturally comparable to WATS3D and could expand into GI applications.
  • Ibex Medical Analytics: AI-powered cancer diagnostics platform deployed in pathology labs worldwide, with FDA-cleared products for breast and prostate cancer detection. Shares the AI-on-histopathology model with WATS3D and represents a potential entrant into the Barrett's esophagus and GI surveillance market.
  • PathAI: AI pathology company partnering with pharmaceutical and diagnostic companies to develop computational pathology products. Operates in the same AI digital pathology space as WATS3D with adjacent oncology applications and could enter GI pathology over time.

Broad incumbents

  • NeoGenomics: Specialty oncology laboratory offering comprehensive molecular and anatomic pathology services, including GI cancer testing. As a broad specialty lab with established payor contracts and a CLIA-certified infrastructure, NeoGenomics could expand into AI-augmented BE/dysplasia testing competing with WATS3D.
  • Exact Sciences: Cancer screening and diagnostics company (Cologuard for CRC screening) with established commercial lab, payor contracts, and direct-to-consumer marketing infrastructure. Could expand from CRC into esophageal cancer screening, overlapping with WATS3D's screening-of-pre-cancer positioning.
  • Medtronic (GI Solutions / Barrx): Owns the Barrx radiofrequency ablation system for treating Barrett's esophagus. As the dominant player in BE management downstream of diagnosis, Medtronic is a natural strategic partner - or competitor if it bundles WATS3D-alternative diagnostics with its ablation franchise.
  • Pentax Medical (HOYA): Endoscope manufacturer developing AI-enhanced endoscopy (i-scan, Optical Enhancement) and exploring AI-powered lesion detection in GI. Provides an OEM/embedded route through which competing AI diagnostic capabilities could be bundled with the endoscopy hardware itself, threatening standalone platforms like WATS3D.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

CDx Diagnostics social profiles

Digital presence

CDx Diagnostics compliance and trust

Trust signal

Compliance3 records

CDx Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CDx Diagnostics leadership team

Management profile

Number of profiles

Profiles5 records

CDx Diagnostics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CDx Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CDx Diagnostics

What does CDx Diagnostics do?

CDx Diagnostics operates a CLIA-certified specialty clinical laboratory that performs the proprietary WATS3D (Wide-Area Transepithelial Sampling with 3D Analysis) test, an AI-powered diagnostic service that uses a specially designed brush to collect wide-area, full-thickness esophageal tissue specimens and applies a neural-network 3D computer-assisted analysis to detect Barrett's esophagus and precancerous cells missed by standard forceps biopsy. The portfolio also includes the OralCDx brush biopsy test for oral precancer detection and the EndoCDx endoscopic diagnostic, with services delivered to gastroenterology practices, hospitals, payors and federal healthcare facilities on a per-procedure reimbursed basis.

Is CDx Diagnostics a public or private company?

CDx Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was CDx Diagnostics founded?

CDx Diagnostics was founded in 2010. It employs 51 to 100 people.

Where is CDx Diagnostics based?

CDx Diagnostics is headquartered in Suffern, United States, in the North America region.

How does CDx Diagnostics make money?

Three revenue lines are on record. WATS3D Per-Test Lab Diagnostic Fee is the primary driver. The others are federal Government Lab Services (GSA) and endoCDx and R&D Pipeline Future Tests.

Who are CDx Diagnostics's main competitors?

Direct peers on record are Mauna Kea Technologies, NinePoint Medical and Cernostics (acquired by Alpine Immune Sciences). Emerging players are Paige.AI, Ibex Medical Analytics and PathAI. Broad incumbents are NeoGenomics, Exact Sciences, Medtronic (GI Solutions / Barrx) and Pentax Medical (HOYA).

Does CDx Diagnostics have an API?

No public API is recorded for CDx Diagnostics.

What industry is CDx Diagnostics in?

CDx Diagnostics's product category is Specialty cancer diagnostics (esophageal and oral precancer detection). Its primary akta.pro industry code is HLAAAMAB, Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy), with a secondary code of HLAAALAF, Companion Diagnostics (CDx) & Therapy Selection Assays. Its NAICS code is 62151 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePaving the Way for Early Esophageal Cancer Detection:CDx Diagnostics announced that Dr. Sidney Olefson of Prima CARE has developed an alternative specimen acquisition technique to enhance the WATS3D test for early esophageal cancer detection, improving cellular adequacy for AI and pathologist analysis. The new sampling approach addresses Barrett's esophagus, a precancerous condition affecting an estimated 3.3 million Americans that can progress to esophageal adenocarcinoma, which has surged over 600% in incidence over the past four decades. Early detection improves survival rates from less than 10% at advanced stages to approximately 48% for localized cases.PR NewswireWATS3D Solution: Barretts and Esophageal Cancer Early Detection Test Reaches 73 Million Covered Lives with New Payer ContractsCDx Diagnostics announced a major expansion of insurance coverage for its WATS3D early esophageal cancer detection solution, adding 17 million covered lives through new agreements with regional and national health insurers to reach a total of 73 million covered lives, representing nearly 20% of the U.S. population. The WATS3D technology uses a specialized biopsy brush, artificial intelligence, and 3D imaging, paired with specially trained pathologists, and has demonstrated in 22 published studies significantly higher detection rates of precancerous conditions compared to traditional methods. The expansion supports early intervention for esophageal adenocarcinoma, which has a five-year mortality rate of approximately 80% and has risen over 700% in the past four decades.PR NewswireWATS3D® Significantly Boosts Barrett's Esophagus and Dysplasia Detection Rates in Landmark Clinical StudyCDx Diagnostics announced publication in The American Journal of Gastroenterology of a pivotal multi-center clinical study demonstrating their WATS3D AI platform significantly improves detection of Barrett's esophagus and dysplasia during GERD screenings. The study of 23,933 patients found that adding WATS3D to standard forceps biopsy identified 20% more Barrett's cases and doubled dysplasia diagnoses, influencing clinical management in over 90% of patients with findings missed by forceps alone.PR Newswire400,000 WATS(3D) Procedures Marks Significant Milestone In Advancing Patient Care & Saving LivesCDx Diagnostics announced it has reached 400,000 WATS3D specimens processed, marking a significant milestone for its AI-enabled diagnostic platform that detects precancerous cells in the esophagus. Clinical studies show the WATS3D technology increases detection of Barrett's esophagus and dysplasia by 153% and 242% respectively when used as an adjunct to standard forceps biopsies. The platform has been included in guidelines from major medical societies including ASGE, AGA, AFS, and SAGES, indicating growing clinical acceptance within the US gastroenterology community.PR NewswireWATS3D Technology Demonstrates Utility as Adjunct to Forceps Biopsies in Post-Eradication Surveillance of Barrett's Esophagus PatientsCDx Diagnostics announced the publication of a study in the journal iGIE demonstrating that its WATS3D AI platform significantly improves the diagnostic yield for detecting intestinal metaplasia and dysplasia in Barrett's esophagus patients post-eradication therapy. The study, analyzing data from 1,114 patients, found that WATS3D detected residual or recurrent conditions missed by standard forceps biopsies in over half of cases involving intestinal metaplasia and nearly all cases involving dysplasia.GlobeNewswireCDx Diagnostics Awarded Federal Supply Schedule ContractCDx Diagnostics was awarded a GSA contract for WATS3D, an AI-powered diagnostic platform for detecting precancerous esophageal cells. The platform is now available to federal healthcare facilities, including the VA, and access to its catalog began December 1. The company plans to apply its technology to prevent cancers of the bile duct, stomach, and colon.GlobeNewswireAmerican Society for Gastrointestinal Endoscopy Includes WATS3D in Its New Practice Guideline for the Screening and Surveillance of Barrett’s EsophagusCDx Diagnostics announced that the American Society for Gastrointestinal Endoscopy included WATS3D in its Barrett's esophagus screening guideline. The company cited over 15,000 patients in studies and claims WATS3D increases dysplasia detection by over 200%.GlobeNewswireNew Data Presented at DDW 2019 Demonstrate That WATS3D Provides Clinical Benefit in Detecting Residual/Recurrent Intestinal Metaplasia in Post-Barrett’s Esophagus Ablation PatientsCDx Diagnostics presented study results at DDW 2019 showing WATS3D increases detection of residual/recurrent intestinal metaplasia by 79% and associated dysplasia by 224% in post-BE ablation patients. The study included 802 patients and 913 endoscopies, and the authors recommend including WATS3D with forceps biopsy for post-ablation tissue sampling.GlobeNewswireCDx Diagnostics Appoints Industry Leader Bill Huffnagle as Chief Executive OfficerCDx Diagnostics appointed Bill Huffnagle as CEO, with Mark Rutenberg transitioning to Chief Scientific Officer. The leadership change aims to drive commercialization of WATS3D, a diagnostic test for Barrett's esophagus, which is on a path to becoming standard practice in esophageal screening.GlobeNewswireHelping to Add Esophageal Adenocarcinoma to the List ofCDx Diagnostics promoted WATS3D, a diagnostic test for Barrett's esophagus and esophageal adenocarcinoma, during Esophageal Cancer Awareness Month. The test has been processed over 200,000 times and increases detection of precancerous cells by over 200% for Barrett's and 100% for dysplasia. The company urged patients to consult gastroenterologists to reduce cancer risk.